1. Home
  2. MBBC vs RNTX Comparison

MBBC vs RNTX Comparison

Compare MBBC & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MBBC

Marathon Bancorp Inc.

N/A

Current Price

$12.73

Market Cap

33.5M

Sector

Finance

ML Signal

N/A

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.56

Market Cap

35.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBBC
RNTX
Founded
1902
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.5M
35.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MBBC
RNTX
Price
$12.73
$1.56
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
3.4K
191.1K
Earning Date
02-22-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.11
N/A
Revenue
$7,299,708.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$111.00
N/A
Revenue Growth
7.77
N/A
52 Week Low
$8.74
$1.02
52 Week High
$12.89
$3.50

Technical Indicators

Market Signals
Indicator
MBBC
RNTX
Relative Strength Index (RSI) 61.26 67.87
Support Level $12.28 $1.12
Resistance Level $12.87 $1.25
Average True Range (ATR) 0.26 0.11
MACD 0.01 0.04
Stochastic Oscillator 87.05 88.82

Price Performance

Historical Comparison
MBBC
RNTX

About MBBC Marathon Bancorp Inc.

Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: